Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

FLAG/VEN as a frontline induction therapy for AML: A multi-centre experience of Anthracycline free approach from India

Mohd Rizwan Shaikh, Mayank Soni Mayank Soni, Krishna Veni, Rashmi Chand, faran Naim, Rohan Halder, Narendra Agrawal, Vipul Sheth, Supriya Adak, Dinesh Bhurani, Rayaz Ahmed

Blood (2025) 146 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2025-3407

Published: 2025

Journal Articles

Real world outcome of nodal T cell non-Hodgkin lymphoma from hematology cancer consortium registry in India

Sreeraj Vasudevan, Anu Korula, Lingaraj Nayak, Mithun Abraham, Alok Shetty, Parathan Karunakaran, Abhilash Menon, Prasanth Ganesan, Gaurav Prakash, Nishil Gowda, Chepsy Philip, Rayaz Ahmed, Sridharan Srinivasan, Prasanna Samuel, Omprakash Karunamurthy, Chandran Nair, Manju Sengar, Vikram Mathews

Blood (2025) 146 (Supplement 1): 7154.

https://doi.org/10.1182/blood-2025-7154

Published: 2025

Journal Articles

Less‑intensive therapy in newly diagnosed acute myeloid leuekmia (AML) in India: Real-world adoption and prognostic utility of ELN‑LI and ELN‑2022 classification

Blood (2025) 146 (Supplement 1): 2829.

https://doi.org/10.1182/blood-2025-2829

Published: 2025

Journal Articles

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Hasmukh Jain, Atharva Karulkar, Devanshi Kalra, Smrithi Ravikumar, Anand Vaibhaw, Shreshtha Shah, Afrin Firfiray, Juber Pendhari, Sameer Melinkeri, Rahul Bhargava, Neeraj Siddarthan, Dr Dinesh Bhurani, Jayachandran P.K., Esha Kaul, Prashant Mehta, Hari Menon, Bhausaheb Bagal, Kunal Goyal, Prakash Shekhawat, Pavan Kumar Boyella, Rakesh Boya, Ram Abhinav, Rayaz Ahmed, Anil Aribandi, Ashwin V Nair, Chandran Nair, Harish Palaparthi, Lingaraj Nayak, Pawan Singh, Priyanshi Pachauri, Rajat Bhattacharya, Rajiv Kumar, Ranjit Sahoo, Sharat Damodar, Vikram Mathews, Vasu Babu Goli, Abhishek Charan, Ajay Gupta, Amul Kapoor, Anupam Chakrapani, Ashish Bakshi, Bijay Prabhakaran Nair, Bilal Kazi, Debranjani Chattopadhyay, Ganesh S. Jaishetwar, Kaushal Kalra, Kishore Kumar, Lekshmon K.S, Madhav Danthala, Mallikarjun Kalashetty, Narendra Anukonda, Naveen Gupta, Nivedita Dhingra, Padmaja Lokireddy, Prasad Narayanan, Parathan Karunakaran, Prasanth Ganesan, Punit Jain, Priyanka Samal, Ramaswamy N.V., Rajan Kapoor, Shyam Aggarwal, Roy J Palatty, Sainath Bhethanabhotla, Sachin Almel, Santhosh Devadas, Sivakumaran Janakiraman, Sudeep V, Sreeraj Vasudevan, Sameer Tulpule, Suraj Chiraniya, Vijay Patil, Sumita Chaudhry, T Raja, Sunu Cyriac, Shishir Seth, Chezhian Subash, Varun Rajan, Alok Shetty, Vishwanath Sathyanarayanan, Mohammed Sadique Ansari, Nishant Tiwari, Shamil Darbar, Supriya Chawkekar, Sushmita Sahay, Manivasagam Sundharam, Ashish Saroha, Moumita Basu, Anjali Jaiswal, Yuktam Yadav, Sakshi Soni, Jayashree Thorat, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Sattva Neelapu, Manju Sengar, Rahul Purwar

Blood (2025) 146 (Supplement 1): 6288.

https://doi.org/10.1182/blood-2025-6288

Published: 2025

Journal Articles

Ulysses Road to Ithaca! MR4.5 at 24 Months Predicts Treatment Free Remission and Survival

Aakanksha Singh, Narendra Agrawal, Rayaz Ahmed, Dinesh Bhurani, Reema Singh, Jyotishankar Raychaudhuri

Blood (2024) 144 (Supplement 1): 6609.

https://doi.org/10.1182/blood-2024-210065

Published: 2024

Journal Articles

Response Adapted Dasatinib De-Escalation Strategy Compared to Upfront Low-Dose Dasatinib: A Prospective Cohort Study

Reema Singh, Sujay Rainchwar, Sakshi Bhatnagar, Nakul Tikare, Roy Palatty, Tribikram Panda, Rayaz Ahmed, Narendra Agrawal, Dinesh Bhurani, Rohan Halder

Blood (2024) 144 (Supplement 1): 3154.

https://doi.org/10.1182/blood-2024-206740

Published: 2024

Journal Articles

CD 19 CAR T-Cell Therapy in R/R B Cell Malignancies : A Real World Experience from CAR T Working Group, Delhi Ncr ,India

Prashant Mehta, Pravas Mishra, Dinesh Bhurani, Vidit Kapoor, Esha Kaul, Rayaz Ahmed, Saphalta Baghmar, Swati Pabbi, Rahul Katharia, Nupur Das, Narendra Agrawal, Rohan Halder, Roy Palatty, Reema Singh, Faran Naim, Jagsahib Kaur

Blood (2024) 144 (Supplement 1): 7772.

https://doi.org/10.1182/blood-2024-205903

Published: 2024

Journal Articles

Prephase Rituximab Followed By Cladirabine in Newly Diagnosed Hairy Cell Leukaemia: A Tertiary Care Center Experience from North India

Tribikram Panda, Reema Singh, Rohan Halder, Roy Palatty, Nakul Tikare, Sakshi Bhatnagar, Rayaz Ahmed, Narendra Agrawal, Dinesh Bhurani

Blood (2024) 144 (Supplement 1): 6335.

https://doi.org/10.1182/blood-2024-204545

Published: 2024

Journal Articles

Gilteritinib for FLT3 Mutated r/r AML: Is the Reality Admirable?

Disha Disha, Aakanksha Singh, Rohan Halder, Roy Palatty, Narendra Agrawal, Tribikram Panda, Nakul Tikare, Rayaz Ahmed, Dinesh Bhurani

Blood (2024) 144 (Supplement 1): 5979.

https://doi.org/10.1182/blood-2024-208207

Published: 2024

Journal Articles

Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment

Blood (2024) 144 (Supplement 1): 3078.

https://doi.org/10.1182/blood-2024-203645

Published: 2024

Journal Articles

A Retrospective Comparative Analysis of Intensive Vs. Non-Intensive Chemotherapy in Treatment Naïve Acute Myeloid Leukemia (AML) Patients in India

Mohd Rizwan Mohamad Anwar Shaikh, Bhumika Singh, Reema Singh, Rohan Halder, Karuna Jha, Tribikram Panda, Rayaz Ahmed, Narendra Agrawal, Dinesh Bhurani

Blood (2023) 142 (Supplement 1): 5842.

https://doi.org/10.1182/blood-2023-188838

Published: 2023

Journal Articles

Risk and Response Adapted Approach for Treatment of Myeloma: Pushing Autologous Transplant Down the Hierarchy

Aakanksha Singh, Reema Singh, Rohan Halder, Karuna Jha, Tribikram Panda, Amir Khan Maroof, Niharika Bhatia, Rayaz Ahmed, Dinesh Bhurani, Narendra Agrawal

Blood (2023) 142 (Supplement 1): 3600.

https://doi.org/10.1182/blood-2023-186745

Published: 2023

Journal Articles

Casting Hope, Defying Odds: Unveiling the Impact of Haplo-Identical Stem Cell Transplant in Myeloid Malignancies - a Tertiary Cancer Care Center Experience

Reema Singh, Sujay Rainchwar, Rohan Halder, Niharika Bhatia, Karuna Jha, Tribikram Panda, Rayaz Ahmed, Dinesh Bhurani, Narendra Agrawal

Blood (2023) 142 (Supplement 1): 6983.

https://doi.org/10.1182/blood-2023-181474

Published: 2023

Journal Articles

Allogeneic Stem Cell Transplant for High-Risk Transfusion Dependent Thalassemia [Tdt] - a Comparative Analysis of Flu/Bu/Cy/ATG Versus Flu/Thio/Treo Regimen

Rohan Halder, Reshmi Harikumar Pillai, Vinayak Hemant Gupta, Sujay Rainchwar, Karuna Jha, Tribikram Panda, Rayaz Ahmed, Narendra Agrawal, Reema Singh, Dinesh Bhurani

Blood (2023) 142 (Supplement 1): 4961.

https://doi.org/10.1182/blood-2023-186817

Published: 2023

Journal Articles

Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Blood (2022) 140 (Supplement 1): 6096–6098.

https://doi.org/10.1182/blood-2022-167099

Published: 2022

Journal Articles

An Observational Prospective Study of Dasatinib 50mg Daily As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia Patients in Chronic Phase

Reema Singh, Rohan Halder, Jyotsna Kapoor, Megha Verma, Pallavi Mehta, Narendra Agrawal, Rayaz Ahmed, Dinesh Bhurani

Blood (2022) 140 (Supplement 1): 12197–12199.

https://doi.org/10.1182/blood-2022-158453

Published: 2022

Journal Articles

Retrospective Study of Treatment Free Remission in Patients with Chronic Myeloid Leukaemia(CML) Treated at Tertiary Care Oncology Centre from India

Megha Verma, Rohan Halder, Reema Singh, Pallavi Mehta, Narendra Agrawal, Rayaz Ahmed, Dinesh Bhurani

Blood (2022) 140 (Supplement 1): 12222.

https://doi.org/10.1182/blood-2022-168574

Published: 2022

Journal Articles

Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial

Blood (2022) 140 (Supplement 1): 6789–6790.

https://doi.org/10.1182/blood-2022-169777

Published: 2022

Journal Articles

Maintenance with Hypomethylating Agents Post-Transplant in Acute Myeloid Leukemia Patients: Safe and Affordable Way to Induce Graft Versus Leukemia Effect

Sujay Rainchwar, Pallavi Mehta, Rayaz Ahmed, Narendra Agrawal, Pritish Chandra Patra

Blood (2022) 140 (Supplement 1): 12902–12903.

https://doi.org/10.1182/blood-2022-164568

Published: 2022

Journal Articles

Hypomethylating Agent Maintenance for Favorable and Intermediate Risk Acute Myeloid Leukemia

Reema Singh, Rohan Halder, Megha Verma, Pallavi Mehta, Narendra Agrawal, Rayaz Ahmed, Dinesh Bhurani

Blood (2022) 140 (Supplement 1): 11713–11715.

https://doi.org/10.1182/blood-2022-162124

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

FLAG/VEN as a frontline induction therapy for AML: A multi-centre experience of Anthracycline free approach from India

Real world outcome of nodal T cell non-Hodgkin lymphoma from hematology cancer consortium registry in India

Less‑intensive therapy in newly diagnosed acute myeloid leuekmia (AML) in India: Real-world adoption and prognostic utility of ELN‑LI and ELN‑2022 classification

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Ulysses Road to Ithaca! MR4.5 at 24 Months Predicts Treatment Free Remission and Survival

Response Adapted Dasatinib De-Escalation Strategy Compared to Upfront Low-Dose Dasatinib: A Prospective Cohort Study

CD 19 CAR T-Cell Therapy in R/R B Cell Malignancies : A Real World Experience from CAR T Working Group, Delhi Ncr ,India

Prephase Rituximab Followed By Cladirabine in Newly Diagnosed Hairy Cell Leukaemia: A Tertiary Care Center Experience from North India

Gilteritinib for FLT3 Mutated r/r AML: Is the Reality Admirable?

Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment

A Retrospective Comparative Analysis of Intensive Vs. Non-Intensive Chemotherapy in Treatment Naïve Acute Myeloid Leukemia (AML) Patients in India

Risk and Response Adapted Approach for Treatment of Myeloma: Pushing Autologous Transplant Down the Hierarchy

Casting Hope, Defying Odds: Unveiling the Impact of Haplo-Identical Stem Cell Transplant in Myeloid Malignancies - a Tertiary Cancer Care Center Experience

Allogeneic Stem Cell Transplant for High-Risk Transfusion Dependent Thalassemia [Tdt] - a Comparative Analysis of Flu/Bu/Cy/ATG Versus Flu/Thio/Treo Regimen

Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

An Observational Prospective Study of Dasatinib 50mg Daily As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia Patients in Chronic Phase

Retrospective Study of Treatment Free Remission in Patients with Chronic Myeloid Leukaemia(CML) Treated at Tertiary Care Oncology Centre from India

Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial

Maintenance with Hypomethylating Agents Post-Transplant in Acute Myeloid Leukemia Patients: Safe and Affordable Way to Induce Graft Versus Leukemia Effect

Hypomethylating Agent Maintenance for Favorable and Intermediate Risk Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only